GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Assembly Biosciences
Assembly Biosciences is a biotech company focused on treating viral diseases such as hepatitis. Its stock price is volatile and dependent on clinical trial results. The chart is a story of the hopes and failures in the development of new antiviral drugs.
Share prices of companies in the market segment - Pharma liver
Assembly Biosciences is a biotechnology company focused on developing new therapeutics for the treatment of chronic hepatitis B and other viral liver diseases. We have classified it in the "Pharma Liver" segment. The chart below shows the overall dynamics in this pharmaceutical sector, where there is a huge need for effective drugs.
Broad Market Index - GURU.Markets
Assembly Biosciences is a biopharmaceutical company developing treatments for chronic hepatitis B and other viral diseases. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how Assembly Bio shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ASMB - Daily change in the company's share price Assembly Biosciences
For Assembly Biosciences, a biopharmaceutical company, change_co is a measure of the sector's inherently high volatility. Each daily change reflects sensitivity to news about clinical trials of its drugs. This metric isn't just noise, but a critical component of the models on System.GURU.Markets that assess risk in innovative medicine.
Daily change in the price of a set of shares in a market segment - Pharma liver
Assembly Biosciences, Inc. is a biotech company. This chart shows the extreme volatility of the sector. Comparison with ASMB, which focuses on viral disease treatments, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Assembly is a biopharmaceutical company specializing in drugs to treat viral diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Assembly's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Assembly Biosciences
Assembly Biosciences' year-to-date performance is a story about the search for a cure for chronic hepatitis B and other viral diseases. Its 12-month market cap is entirely dependent on clinical trial data. Any progress in the development of its antiviral drugs could lead to significant growth, as the company targets huge global markets.
Annual dynamics of market capitalization of the market segment - Pharma liver
Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing drugs to treat viral diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotechnology sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Assembly Biosciences is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Assembly Biosciences
The price of Assembly, a biopharmaceutical company, is speculative. Monthly fluctuations on the chart reflect not revenue, but news about the progress of clinical trials of its drugs for the treatment of viral diseases, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Pharma liver
Assembly Biosciences is a biopharmaceutical company focused on treating viral diseases, particularly hepatitis B and D. Its future depends on the success of clinical trials. The pharmaceutical sector chart will reflect overall investor interest in infectious disease treatment, providing important context for assessing Assembly Bio's scientific and commercial potential.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Assembly Biosciences is working on a treatment for chronic liver disease. Like many biotech companies, its shares are driven by anticipation of clinical trial news. Investors are buying not current revenue, but the hope of a future blockbuster. Therefore, the company's monthly stock price may be completely unrelated to the broader market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Assembly Biosciences
Assembly Biosciences, a biotech company focused on treating viral diseases such as hepatitis, exhibits high volatility. Its weekly stock price is almost entirely dependent on clinical trial results and strategic partnerships with major pharmaceutical companies.
Weekly dynamics of market capitalization of the market segment - Pharma liver
Biotech companies focused on treating liver diseases, like Assembly Biosciences, are driven by news of clinical trials. The success or failure of one player often impacts the entire niche. The chart below shows this overall pulse, allowing one to assess how promising the market perceives Assembly's technology compared to its competitors.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Assembly Biosciences is a biotech company focused on treating viral diseases such as hepatitis. Its shares are driven by news of clinical trials. The chart will show how much their performance is detached from the broader market and driven solely by scientific events.
Market capitalization of the company, segment and market as a whole
ASMB - Market capitalization of the company Assembly Biosciences
Assembly Biosciences' market capitalization chart reflects investors' assessment of its scientific approach to treating viral diseases such as hepatitis B and herpes. Its dynamics reflect progress in clinical trials and the market's confidence in its new mechanisms of action. Its value reflects a bet that its drugs will offer better results than existing therapies.
ASMB - Share of the company's market capitalization Assembly Biosciences within the market segment - Pharma liver
Assembly Biosciences is a biopharmaceutical company focused on treating liver diseases, particularly hepatitis B. Within its segment, its market capitalization reflects the potential of its scientific developments. The dynamics of this indicator reflect the market's sensitive reaction to clinical trial results, which can either boost or derail the company's value.
Market capitalization of the market segment - Pharma liver
This chart shows the overall market capitalization of the entire biotech sector focused on liver diseases. For Assembly Biosciences, which is developing drugs for hepatitis B, this line is a map of hope. Its fluctuations reflect the industry's successes and setbacks in the fight against viral diseases, a backdrop against which the company conducts its risky but important research.
Market capitalization of all companies included in a broad market index - GURU.Markets
Assembly Biosciences develops drugs for viral diseases such as hepatitis. Its market capitalization is determined by its research and potential to cure chronic infections. This market share is determined by the share of the overall market devoted to fighting viral threats.
Book value capitalization of the company, segment and market as a whole
ASMB - Book value capitalization of the company Assembly Biosciences
Assembly Biosciences fights viral diseases such as hepatitis. Its book value is its financial resources for research. It consists of cash that allows the company to develop and conduct clinical trials of new drugs. How has this research budget changed? The chart below shows this trend.
ASMB - Share of the company's book capitalization Assembly Biosciences within the market segment - Pharma liver
Assembly Biosciences fights viral diseases, and its scientific research requires a material base. This includes modern laboratories and an in-house platform for the discovery and development of next-generation small molecules. The chart shows the company's share of the physical R&D infrastructure necessary for the creation of antiviral drugs.
Market segment balance sheet capitalization - Pharma liver
Assembly Biosciences, a clinical-stage biopharmaceutical company, has minimal physical assets. Its business is focused on R&D. The BCap_Seg chart for the biotech sector, which consists of hundreds of similar companies, is generally low, as its primary capital is intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
Assembly Biosciences' capital comes not from its plants, but from its scientific platform and development pipeline of small-molecule drugs for the treatment of viral diseases, particularly herpes. Its book value reflects its investment in R&D. The chart shows how this knowledge-intensive asset is valued within the biotech sector.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Assembly Biosciences
Assembly Bio's balance sheet is its R&D capital. Its market valuation is the belief in its new approach to treating viral diseases like herpes. Its schedule is a bet that its science will succeed where others have failed.
Market to book capitalization ratio in a market segment - Pharma liver
Assembly Biosciences is a biotech company developing drugs to treat viral diseases. Its valuation on this chart reflects investors' faith in its scientific platform, despite past setbacks. This is a bet on future clinical successes and new approaches.
Market to book capitalization ratio for the market as a whole
Assembly Biosciences is a biotech company working on treatments for viral diseases such as hepatitis. Its market value depends on progress in clinical trials. This chart shows how expectations and development news drive its valuation, independent of its current tangible assets.
Debts of the company, segment and market as a whole
ASMB - Company debts Assembly Biosciences
Assembly Biosciences, a biotech company focused on treating viral diseases, uses capital to fund its expensive clinical trials. This chart shows how the company manages its resources to advance its research programs through the complex and risky drug development process, hoping for a breakthrough.
Market segment debts - Pharma liver
Assembly Biosciences is a clinical-stage biotech company focused on treating viral diseases such as hepatitis. For companies like this, a lack of revenue and high research costs make raising debt undesirable. This chart likely shows the company is following the industry standard of equity financing.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Assembly Biosciences
Assembly Biosciences is a biotech company focused on treating liver diseases. Its financial model is typical for the industry: heavily investing in research while waiting for a breakthrough. This chart shows its level of dependence on external capital. It helps assess the company's resilience to continue development in the event of delays or setbacks.
Market segment debt to market segment book capitalization - Pharma liver
Assembly Biosciences is developing drugs to treat serious viral diseases such as hepatitis B. Fighting viruses is a complex scientific challenge. This chart shows how aggressively the biotech sector uses debt to fund R&D, providing context for assessing Assembly Biosciences' risks and potential.
Debt to book value of all companies in the market
Assembly Biosciences, a biopharmaceutical company focused on viral diseases, is in the clinical trials phase, requiring ongoing funding. This chart, reflecting the overall market debt burden, allows one to assess how typical the company's financial strategy is for the biotech sector, where revenues can take years to materialize.
P/E of the company, segment and market as a whole
P/E - Assembly Biosciences
Assembly Biosciences is a biotechnology company focused on developing therapeutics for chronic hepatitis B and other viral diseases. This chart shows how the market evaluates its scientific approach. This evaluation is based on clinical trial data and the potential of its drugs to offer a functional cure.
P/E of the market segment - Pharma liver
Assembly Biosciences develops antiviral drugs. This chart shows the average valuation for the biotech sector. It serves as a backdrop for Assembly's valuation: investors are looking not at its profits, but at the potential of its scientific platform to offer a functional cure for chronic viral infections.
P/E of the market as a whole
Assembly Biosciences is a biopharmaceutical company focused on developing small-molecule drugs for the treatment of viral diseases, particularly hepatitis B and herpes. This chart reflects the overall risk appetite of investors in biotech. It helps us understand whether Assembly Biosciences' valuation is based on the potential of its scientific developments or whether it moves in line with overall sector sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Assembly Biosciences
Assembly Biosciences is a biotech company focused on developing therapies for serious viral diseases such as hepatitis. Future profits depend on the success of its clinical trials. This chart shows investor expectations for a scientific breakthrough and the development of effective antiviral drugs.
%20P%2FE%20Assembly%20Biosciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Assembly-Biosciences&v=1772541368099 "Chart of the company's future (projected) P/E Assembly Biosciences")
Future (projected) P/E of the market segment - Pharma liver
Assembly Biosciences is focused on developing drugs to treat serious viral diseases such as hepatitis B and herpes. The data here reflects the analysts' collective bets on the success of its clinical programs. It is a barometer of expectations that its innovative approaches will lead to the development of a functional cure or effective therapy.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-liver&v=1772541368213 "Future (projected) P/E graph of the market segment - Pharma liver")
Future (projected) P/E of the market as a whole
Assembly Biosciences is working on developing drugs for viral diseases such as hepatitis. This is a high-risk area with enormous potential. This sentiment chart shows how willing the market is to fund biotech companies tackling complex and global health issues.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772541368290 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Assembly Biosciences
Assembly Biosciences is a biotechnology company focused on developing therapies for liver diseases such as hepatitis. This chart shows financial expenditures on research and development. It reflects investments in clinical programs whose success could lead to the creation of a new standard of care.
Profit of companies in the market segment - Pharma liver
Assembly Biosciences is a biopharmaceutical company focused on developing drugs for liver diseases, particularly hepatitis B. Being in the clinical stage, its financial performance is driven by research expenditures. Success in this area could yield enormous profits, reflecting the high potential of the biotech sector.
Overall market profit
Assembly Biosciences is a biotech company focused on developing drugs for viral diseases such as hepatitis. Its success depends on the results of clinical trials. The overall economic situation, reflected in this chart, does not affect the demand for its drugs, but it does determine the investment climate, which is important for funding its research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Assembly Biosciences
Assembly Biosciences is a biotechnology company focused on developing therapies for serious viral diseases such as hepatitis B. This chart reflects analysts' speculative expectations. Future profit projections depend on the success of clinical trials and potential breakthroughs in the treatment of chronic infections.
%20profit%20of%20the%20company%20Assembly%20Biosciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Assembly-Biosciences&v=1772541368516 "Graph of future (projected) profit of the company Assembly Biosciences")
Future (predicted) profit of companies in the market segment - Pharma liver
Assembly Biosciences is focused on developing drugs to treat chronic hepatitis B and other viral diseases. The profitability forecasts for the pharmaceutical industry, shown on the chart, provide a general overview. This chart helps assess Assembly's potential to create a functional cure for hepatitis B, which affects millions of people.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-liver&v=1772541368601 "Graph of future (predicted) profits of companies in a market segment - Pharma liver")
Future (predicted) profit of the market as a whole
Assembly Biosciences is a biotech company focused on developing therapeutics for viral diseases such as hepatitis. Funding for its research and development is highly dependent on market sentiment and capital availability. A positive economic environment, illustrated by this chart, facilitates investment in biotech.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772541368712 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Assembly Biosciences
Assembly Biosciences is a biotech company focused on developing drugs to treat viral diseases such as hepatitis B. Being in the clinical stage, it may not generate revenue. This chart shows how investors view its scientific approach and the potential of its drug candidates to combat chronic infections.
P/S market segment - Pharma liver
Assembly Biosciences is a biotechnology company focused on developing innovative therapeutics for the treatment of viral diseases, particularly hepatitis B and D. This metric reflects the average revenue estimate for the sector and helps understand how much confidence the market has in the company's scientific potential compared to its peers.
P/S of the market as a whole
Assembly Biosciences is a biotech company focused on developing new treatments for viral diseases, particularly hepatitis B and herpes. The company's potential depends on the success of its clinical programs. This chart correlates the market's valuation of the company with its actual revenues, which is important for contextualizing biotech analysis.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Assembly Biosciences
Assembly Biosciences is a biotechnology company focused on developing therapies for viral diseases such as hepatitis B. This chart shows investor estimates of its potential future revenue. This estimate depends on the success of its clinical programs and the demand for new treatments.
%20P%2FS%20Assembly%20Biosciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Assembly-Biosciences&v=1772541369139 "The graph of the company's future (projected) P/S Assembly Biosciences")
Future (projected) P/S of the market segment - Pharma liver
Assembly Biosciences is a biotech company focused on developing therapeutics for viral diseases such as hepatitis B. This chart compares market expectations for its future revenue with those of other pharmaceutical companies in the liver treatment field. The valuation reflects investor expectations for the success of its clinical programs.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20liver&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-liver&v=1772541369270 "Future (projected) P/S market segment graph - Pharma liver")
Future (projected) P/S of the market as a whole
Assembly Biosciences is a clinical-stage biotechnology company focused on developing drugs to treat viral diseases such as hepatitis. Its value depends on the success of its research programs. This graph of overall market expectations for Assembly Bio is merely a backdrop; its future is determined by the results of clinical trials.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772541369461 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Assembly Biosciences
This chart shows the revenue of Assembly Biosciences, a biotech company focused on developing drugs to treat viral diseases such as hepatitis B. Being in the clinical stage, the company has no stable sales revenue. Any revenue likely comes from co-development partners, which is vital for funding R&D.
Sales of companies in the market segment - Pharma liver
Assembly Biosciences is a clinical-stage biopharmaceutical company focused on developing new treatments for chronic hepatitis B and other viral diseases. This chart shows revenue in the liver pharmaceuticals sector. It reflects the enormous unmet need for a therapy capable of curing hepatitis B, which is the focus of Assembly's research.
Overall market sales
Assembly Biosciences is a biotech company focused on treating viral diseases such as hepatitis B. Its value is determined by progress in clinical trials. The overall economic situation, reflected in this chart, does not directly impact demand for treatment, but it does create a backdrop for attracting investment and influences future pharmaceutical pricing.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Assembly Biosciences
Assembly Biosciences is a clinical-stage biotechnology company focused on developing new treatments for viral diseases such as hepatitis. This revenue projection chart reflects expectations for its research and development. Its dynamics depend on analysts' confidence in the successful clinical trial results of its drug candidates.
%20sales%20of%20the%20company%20Assembly%20Biosciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Assembly-Biosciences&v=1772541369699 "Schedule of future (projected) sales of the company Assembly Biosciences")
Future (projected) sales of companies in the market segment - Pharma liver
Assembly Biosciences is a clinical-stage biotechnology company focused on developing new treatments for chronic hepatitis B and other serious viral liver diseases. This chart shows projected revenue for the liver pharmaceutical sector, reflecting the need for more effective antiviral therapies.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-liver&v=1772541369817 "Schedule of future (projected) sales of companies in the market segment - Pharma liver")
Future (projected) sales of the market as a whole
Assembly Biosciences is a biotechnology company focused on developing drugs to treat viral diseases such as hepatitis. Its success depends on the results of clinical trials. A positive economic environment is stimulating investment in the biotechnology sector, allowing the company to fund its research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772541369899 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Assembly Biosciences
Assembly Biosciences is a biotech company focused on treating viral diseases such as hepatitis. It is in clinical trials. This chart shows its R&D investment. Negative values reflect the cost of developing drugs that could dramatically change patients' lives and generate revenue.
Market segment marginality - Pharma liver
Assembly Biosciences is a biopharmaceutical company focused on developing therapeutics for viral diseases such as hepatitis B. This chart compares its operating efficiency to other biotech companies. Its current competitive advantage may be due to upfront payments from drug development partners.
Market marginality as a whole
Assembly Biosciences is a biotech company focused on developing treatments for viral diseases such as hepatitis. Its success is determined by scientific data and progress in clinical trials, not by the economic situation, as reflected in this chart. The need for new antiviral drugs is constant and not dependent on business cycles.
Employees in the company, segment and market as a whole
Number of employees in the company Assembly Biosciences
Assembly Biosciences is a biotechnology company focused on developing drugs to treat viral diseases such as hepatitis. This graph shows the team of scientists. Headcount dynamics may reflect ups and downs related to clinical trial results and strategic changes in R&D programs.
Share of the company's employees Assembly Biosciences within the market segment - Pharma liver
Assembly Biosciences is a biotechnology company focused on developing drugs for viral diseases. Its current focus is on scientific research, conducted by a small but highly qualified team. This underscores its research-intensive nature: value is created in the laboratory, not through the scale of its workforce.
Number of employees in the market segment - Pharma liver
Assembly Biosciences is a biotechnology company focused on developing drugs to treat viral diseases such as hepatitis B and herpes. This graph illustrates the long and risky path to developing antiviral drugs. The research staff's growth depends on clinical trial results and the competitive environment in this complex field of medicine.
Number of employees in the market as a whole
Assembly Biosciences is a biotech company focused on treating viral diseases such as hepatitis B. Its staff consists of scientists and researchers. This employment chart highlights that in the pharmaceutical world, hiring trends are driven by progress in clinical trials and strategic partnerships, rather than general economic cycles.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Assembly Biosciences (ASMB)
Assembly Biosciences is a biotech company focused on developing therapies for viral diseases, particularly hepatitis B and herpes. This chart shows the enormous market value per scientist. This is typical for clinical-stage biotech, where investors evaluate the potential of scientific developments rather than current revenue.
%20of%20the%20company%20Assembly%20Biosciences%20(ASMB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Assembly-Biosciences-ASMB&v=1772541370630 "Chart of market capitalization per employee (in thousands of dollars) of the company Assembly Biosciences (ASMB)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma liver
Assembly Biosciences is a biopharmaceutical company focused on treating liver diseases, particularly hepatitis B. This chart reflects market expectations for their scientific developments. The high market capitalization per employee compared to the sector may indicate that investors believe in the breakthrough potential of their therapeutic approach.
%20by%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-liver&v=1772541370661 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma liver")
Market capitalization per employee (in thousands of dollars) for the overall market
Assembly Biosciences is a biopharmaceutical company focused on treating viral diseases such as hepatitis. This metric reflects a business built on scientific research. Its market capitalization is a function of the prospects of its developments. A small team of scientists is working on developing drugs with a potentially huge market.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772541370666 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Assembly Biosciences (ASMB)
Assembly Biosciences is a clinical-stage biotech company focused on treating viral diseases, such as herpes. They are not profitable. This chart shows their loss per employee. This is a standard indicator of the "burn rate" of capital spent on expensive clinical trials.
%20Chart%20Assembly%20Biosciences%20(ASMB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Assembly-Biosciences-ASMB&v=1772541370752 "Company Profit Per Employee (in thousands of dollars) Chart Assembly Biosciences (ASMB)")
Profit per employee (in thousands of dollars) in the market segment - Pharma liver
Assembly Biosciences is a clinical-stage biotech company specializing in liver disease treatments. The company has no profit, only R&D expenses. This chart provides an industry benchmark for R&D spending per employee, and ASMB's metric demonstrates their own capital burn rate in this area.
%20in%20the%20market%20segment%20-%20Pharma%20liver&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-liver&v=1772541370777 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma liver")
Profit per employee (in thousands of dollars) for the market as a whole
Assembly Biosciences is a biotech company focused on treating liver diseases such as hepatitis B. They are currently in clinical trials. This chart doesn't reflect profit, but rather shows the company's capital burn rate. The negative per-employee figure represents the cost of maintaining a research team in the race to create a new standard of treatment.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772541370844 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Assembly Biosciences (ASMB)
Assembly Biosciences is a biopharmaceutical company focused on treating viral diseases such as hepatitis. This chart illustrates the company's clinical-stage business. Low or no revenue per employee is normal for a company investing all its resources in research and development.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Assembly-Biosciences-ASMB&v=1772541370846 "Sales chart per company employee Assembly Biosciences (ASMB)")
Sales per employee in the market segment - Pharma liver
Assembly Biosciences (ASMB) is a clinical-stage biotech company specializing in developing drugs to treat serious viral diseases such as hepatitis B and C. This chart shows how much revenue (from partnerships) each employee (scientist) generates. This is an indicator of the productivity of their R&D platform compared to other biotechs in the field.
Sales per employee for the market as a whole
Assembly Biosciences is a biopharmaceutical company focused on developing therapies for serious viral diseases, particularly hepatitis B. It is a clinical-stage R&D company. The company has no commercial revenue from drug sales. This metric is currently close to zero and does not reflect operating activities.
Short shares by company, segment and market as a whole
Shares shorted by company Assembly Biosciences (ASMB)
Assembly Biosciences is a biotech company focused on treating liver diseases, specifically hepatitis B. This chart shows bearish bets. Bears are betting on failure in clinical trials. Developing a cure for hepatitis B is a very complex task, and many companies have failed along the way.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Assembly-Biosciences-ASMB&v=1772541370986 "Short Shares Chart for the Company Assembly Biosciences (ASMB)")
Shares shorted by market segment - Pharma liver
Assembly Biosciences is a biotech company focused on developing drugs against viral diseases, particularly hepatitis B. This chart shows bearish sentiment. The "shorts" here represent investors' bets that their hepatitis treatment approaches will fail in clinical trials.
Shares shorted by the overall market
Assembly Biosciences focuses on treating viral diseases such as hepatitis B. It's a biotech with a long development cycle. This chart illustrates the overall level of market pessimism. When fear prevails, investors often lose patience with biotechs that take years to gain FDA approval and shift to "safer" sectors.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Assembly Biosciences (ASMB)
Assembly Biosciences is a clinical-stage biotech company. Its shares are extremely sensitive to trial news. This chart can surge above 70 on positive R&D data. Oversold territory (<30) often reflects research setbacks or a general aversion to risk in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Assembly-Biosciences-ASMB&v=1772541371130 "RSI 14 indicator chart for the company's stock Assembly Biosciences (ASMB)")
RSI 14 Market Segment - Pharma liver
Assembly Bio (ASMB) is a biotech company focused on treating *viral* diseases (hepatitis B). The RSI_14_Seg for "Pharma liver" (biotech) shows the overall sentiment. The chart helps us understand: is ASMB's volatility a reaction to its clinical trials, or is the entire sector overheated (or oversold)?
RSI 14 for the overall market
Assembly Bio (ASMB) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ASMB (Assembly Biosciences)
Assembly Biosciences (ASMB) is a biotech company focused on developing antiviral drugs, particularly for the treatment of hepatitis B and D. This chart shows the average 12-month forecast. It reflects analysts' speculative assessment of the likelihood of success in the company's clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ASMB-Assembly-Biosciences&v=1772541371277 "A chart showing analyst consensus forecasts for the expected stock price. ASMB (Assembly Biosciences)")
The difference between the consensus estimate and the actual stock price ASMB (Assembly Biosciences)
Assembly Biosciences is a clinical-stage biotech company. After years of failures in treating Hepatitis B, they have rebooted and are now using their R&D expertise to attack other viral diseases (such as herpes). This chart shows how much analysts believe in this second chance and their new, earlier R&D pipeline.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ASMB-Assembly-Biosciences&v=1772541371321 "A chart showing the difference between the consensus forecast and the actual stock price. ASMB (Assembly Biosciences)")
Analyst consensus forecast for stock prices by market segment - Pharma liver
Assembly Biosciences is a biotechnology company focused on developing new treatments for viral diseases, particularly hepatitis B. This chart shows analysts' overall expectations for the liver pharmaceutical sector. It reflects whether experts believe a breakthrough in the treatment of chronic hepatitis B is possible.
Analysts' consensus forecast for the overall market share price
Assembly Biosciences (ASMB) is a clinical-stage biopharmaceutical company focused on treating viral diseases such as hepatitis B. This is a high-risk scientific endeavor. This chart shows the overall risk appetite in the market. It is an indicator of the "open" or "closed" funding window for speculative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Assembly Biosciences
Assembly Bio is a clinical-stage biotech focused on targeting chronic viral diseases, primarily hepatitis B (HBV) and hepatitis D (HDV). This chart represents pure R&D betting and likely reflects the market's confidence in their scientific platform (aimed at a cure, not a treatment) and their early clinical data.
AKIMA Market Segment Index - Pharma liver
Assembly Bio (ASMB) is a clinical-stage biotech focused on virology; following its failure in Hepatitis B, the company is developing new antiviral drugs (including herpes). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this R&D platform (ASMB) differentiate itself from the average pharma company?
The AKIM Index for the overall market
Assembly Biosciences is a biotech company developing next-generation antiviral drugs (for herpes and hepatitis B). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this scientific story, which is moving toward a broader pipeline, fits within the context of the overall economic trends affecting the sector.
